Anocca has announced the closing of a USD 47 million (SEK 400 million) Series B financing to further advance the company’s industrialised cellular biology platform and progress its pipeline of TCR-T cellular therapies into Phase I/IIa clinical trials.
The financing, led by advisor Danske Bank, brings together a group of investors, with Swedbank Robur Ny Teknik, Ramsbury Invest and significant family offices including those of Harald Mix and Robert Andreen joining existing investors including Mellby Gård, Nidoco and co-founder Mikael Blomqvist via Michano.
Accelerate the oncology pipeline
“This financing round, which takes us to well over $100m raised since our founding in 2014, is further strong endorsement of our pioneering approach to industrialised high-precision analysis of T-cell biology. The team has built and operationalised an industry-leading suite of unique technologies to generate efficient and systematic TCR-T cell therapy pipelines. We will use this substantial financing to accelerate our broad oncology pipeline into the clinic with our in-house manufacturing capabilities. We continue to methodically move towards our vision of delivering blockbuster franchises of next generation T-cell immunotherapies for the treatment of multiple cancer types,” says Anocca’s CEO and co-founder Reagan Jarvis.
Cellular biology platform
The company’s industrialised cellular biology platform replicates human T-cell biology in the laboratory, to generate targeted T-cell therapies with broad applicability in oncology, infectious diseases and autoimmune disorders, the company states. The technology platform is comprised of a number of cell biology and molecular genetics technologies and enables the scalable high-precision analysis needed to develop highly targeted therapeutics that leverage T-cell immunity. The platform is underpinned by information management and bioinformatic software tools developed in-house.
Anocca’s platform has delivered a broad pipeline of T-cell receptor (TCR) assets to generate novel TCR-modified T-cell therapies (TCR-T) against multiple antigen classes, including targets that are shared amongst tumours, against specific genetic mutations that drive cancer, and against viruses that cause cancer, the company states.
Photo of Reagan Jarvis